Compare J.B.Chemicals with Glenmark Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

J.B.CHEMICALS vs GLENMARK PHARMA - Comparison Results

J.B.CHEMICALS     Change

JB Chemicals and Pharmaceuticals Limited (JBCPL), the flagship of the Unique Group, is one of the India's leading transnational pharmaceutical company. The company has 11 manufacturing facilities at four locations in India (Belapur, Ankleshwar, Panol... More

GLENMARK PHARMA 
   Change

Glenmark's focus areas are dermatology, gynecology, pediatrics and diabetics. The domestic formulations business contributed about 35% to revenues in FY07. On the international front, besides exports to the semi-regulated markets, the company has bee... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    J.B.CHEMICALS GLENMARK PHARMA J.B.CHEMICALS/
GLENMARK PHARMA
 
P/E (TTM) x 22.7 15.7 144.4% View Chart
P/BV x 4.2 2.2 194.0% View Chart
Dividend Yield % 0.3 0.5 60.2%  

Financials

 J.B.CHEMICALS   GLENMARK PHARMA
EQUITY SHARE DATA
    J.B.CHEMICALS
Mar-18
GLENMARK PHARMA
Mar-19
J.B.CHEMICALS/
GLENMARK PHARMA
5-Yr Chart
Click to enlarge
High Rs363712 51.0%   
Low Rs255484 52.7%   
Sales per share (Unadj.) Rs169.1349.6 48.4%  
Earnings per share (Unadj.) Rs16.632.8 50.6%  
Cash flow per share (Unadj.) Rs23.444.3 52.8%  
Dividends per share (Unadj.) Rs2.002.00 100.0%  
Dividend yield (eoy) %0.60.3 193.4%  
Book value per share (Unadj.) Rs172.5198.6 86.8%  
Shares outstanding (eoy) m83.57282.17 29.6%   
Bonus/Rights/Conversions BB--  
Price / Sales ratio x1.81.7 106.9%   
Avg P/E ratio x18.618.2 102.1%  
P/CF ratio (eoy) x13.213.5 97.9%  
Price / Book Value ratio x1.83.0 59.6%  
Dividend payout %12.06.1 197.5%   
Avg Mkt Cap Rs m25,827168,625 15.3%   
No. of employees `0003.812.0 31.3%   
Total wages/salary Rs m2,51120,561 12.2%   
Avg. sales/employee Rs Th3,747.48,196.0 45.7%   
Avg. wages/employee Rs Th665.71,708.1 39.0%   
Avg. net profit/employee Rs Th367.8768.5 47.9%   
INCOME DATA
Net Sales Rs m14,13598,655 14.3%  
Other income Rs m3662,081 17.6%   
Total revenues Rs m14,501100,736 14.4%   
Gross profit Rs m2,17815,858 13.7%  
Depreciation Rs m5703,259 17.5%   
Interest Rs m353,346 1.0%   
Profit before tax Rs m1,94011,335 17.1%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m01,672 0.0%   
Tax Rs m5523,756 14.7%   
Profit after tax Rs m1,3879,250 15.0%  
Gross profit margin %15.416.1 95.9%  
Effective tax rate %28.533.1 85.9%   
Net profit margin %9.89.4 104.7%  
BALANCE SHEET DATA
Current assets Rs m10,47066,968 15.6%   
Current liabilities Rs m2,74940,211 6.8%   
Net working cap to sales %54.627.1 201.4%  
Current ratio x3.81.7 228.7%  
Inventory Days Days5583 66.2%  
Debtors Days Days7881 95.6%  
Net fixed assets Rs m5,81133,322 17.4%   
Share capital Rs m167282 59.2%   
"Free" reserves Rs m14,24855,770 25.5%   
Net worth Rs m14,41656,052 25.7%   
Long term debt Rs m035,738 0.0%   
Total assets Rs m17,649132,888 13.3%  
Interest coverage x56.64.4 1,289.4%   
Debt to equity ratio x00.6 0.0%  
Sales to assets ratio x0.80.7 107.9%   
Return on assets %8.19.5 85.0%  
Return on equity %9.616.5 58.3%  
Return on capital %13.717.8 76.9%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m6,16462,998 9.8%   
Fx outflow Rs m1,33422,859 5.8%   
Net fx Rs m4,82940,140 12.0%   
CASH FLOW
From Operations Rs m1,23113,242 9.3%  
From Investments Rs m-208-6,990 3.0%  
From Financial Activity Rs m-595-7,387 8.1%  
Net Cashflow Rs m427-2,971 -14.4%  

Share Holding

Indian Promoters % 55.4 48.3 114.7%  
Foreign collaborators % 0.3 0.0 -  
Indian inst/Mut Fund % 3.4 6.9 49.1%  
FIIs % 3.9 34.4 11.3%  
ADR/GDR % 0.0 0.0 -  
Free float % 37.0 10.5 352.4%  
Shareholders   30,437 56,727 53.7%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare J.B.CHEMICALS With:   ASTRAZENECA PHARMA  ALEMBIC PHARMA  CADILA HEALTHCARE  GSK PHARMA  PANACEA BIOTECH  

Compare J.B.CHEMICALS With:   MYLAN (US)  ADCOCK INGRAM (S. Africa)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 178 Points Higher; Telecom and Power Stocks Witness Buying(Closing)

Indian share markets witnessed buying interest throughout the day today and ended on a positive note.

Related Views on News

GLENMARK PHARMA Announces Quarterly Results (3QFY20); Net Profit Up 64.0% (Quarterly Result Update)

Feb 19, 2020 | Updated on Feb 19, 2020

For the quarter ended December 2019, GLENMARK PHARMA has posted a net profit of Rs 2 bn (up 64.0% YoY). Sales on the other hand came in at Rs 27 bn (up 7.1% YoY). Read on for a complete analysis of GLENMARK PHARMA's quarterly results.

J.B.CHEMICALS Announces Quarterly Results (3QFY20); Net Profit Up 34.1% (Quarterly Result Update)

Feb 6, 2020 | Updated on Feb 6, 2020

For the quarter ended December 2019, J.B.CHEMICALS has posted a net profit of Rs 622 m (up 34.1% YoY). Sales on the other hand came in at Rs 4 bn (up 9.3% YoY). Read on for a complete analysis of J.B.CHEMICALS's quarterly results.

GLENMARK PHARMA 2018-19 Annual Report Analysis (Annual Result Update)

Sep 5, 2019 | Updated on Sep 5, 2019

Here's an analysis of the annual report of GLENMARK PHARMA for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of GLENMARK PHARMA. Also includes updates on the valuation of GLENMARK PHARMA.

GLENMARK PHARMA Announces Quarterly Results (1QFY20); Net Profit Down 53.1% (Quarterly Result Update)

Aug 28, 2019 | Updated on Aug 28, 2019

For the quarter ended June 2019, GLENMARK PHARMA has posted a net profit of Rs 1 bn (down 53.1% YoY). Sales on the other hand came in at Rs 23 bn (up 7.3% YoY). Read on for a complete analysis of GLENMARK PHARMA's quarterly results.

GLENMARK PHARMA Announces Quarterly Results (4QFY19); Net Profit Up 6.6% (Quarterly Result Update)

Jun 3, 2019 | Updated on Jun 3, 2019

For the quarter ended March 2019, GLENMARK PHARMA has posted a net profit of Rs 2 bn (up 6.6% YoY). Sales on the other hand came in at Rs 26 bn (up 12.4% YoY). Read on for a complete analysis of GLENMARK PHARMA's quarterly results.

More Views on News

Most Popular

How to Find the Best Stocks for Day Trading - 1(Fast Profits Daily)

Jul 2, 2020

In the first of two videos, I'll show you how to identify the best stocks for intraday trading.

Be Prepared to Profit from the Coming Crash in Oil Prices(Fast Profits Daily)

Jun 25, 2020

The stability in crude oil prices will not last much longer. Be ready to make fast profits when the time comes to short crude.

Tata Motors Tripled in 18 Months but You Can Do Even Better. Here's How...(Profit Hunter)

Jun 24, 2020

Rahul is ready for a repeat of his famous 2008 Tata Motors call.

Two Agri Stocks Are Likely to Outperform Even in this Market(Profit Hunter)

Jul 2, 2020

Why we have recommended two agriculture stocks for our Hidden Treasure subscribers. Read on...

More

India's #1 Trader
Reveals His Secrets

The Secret to Increasing Your Trading Profits Today
Get this Special Report, The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

J.B.CHEMICALS SHARE PRICE


Jul 3, 2020 (Close)

TRACK J.B.CHEMICALS

  • Track your investment in J.B.CHEMICALS with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

J.B.CHEMICALS 5-YR ANALYSIS

COMPARE J.B.CHEMICALS WITH

MARKET STATS